Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05930301
Other study ID # WuxiPH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date December 1, 2024

Study information

Verified date June 2023
Source Wuxi People's Hospital
Contact Peihua Lu, doctor
Phone 13621500031
Email 13625653@qq.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.


Read more »

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Wuxi People's Hospital Wuxi Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Peihua Lu Suzhou Royaltechmed Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The objective remission rate assessed by the independent review committee according to RECIST1.1. Main efficacy indicators The time from the first administration to the first observation of disease recurrence or death of the patient was evaluated for up to 36 weeks.
Secondary Disease control rate (DCR) Secondary efficacy indicators The percentage of subjects who reached CR, PR and SD after treatment was analyzed.No more than 36 weeks.
Secondary Progression-free survival (PFS) Secondary efficacy indicators The time interval between the patient's first treatment and the first record of disease progression or death.No more than 36 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05952167 - Evaluation of the Impact of Tractions vs. Placebo Tractions in Patients With Cervical Radiculopathy N/A
Completed NCT02716389 - Cervical Kinematics' Reliability: Zero Positioning Using a 3-D-bulls Eye Spirit Level N/A
Recruiting NCT05893745 - Effectiveness of Dermoneuromodulation Techniques in Patients With Non-specific Chronic Neck Pain: A Randomized Controlled Trial N/A
Completed NCT05871047 - Prevalence of Nerd Neck Between Different Students at Taibah University, Saudi Arabia
Completed NCT05280847 - Analysis of Injectate Spread During Erector Spinae Block N/A
Completed NCT00972205 - Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors N/A
Completed NCT04594876 - Cervical Epidural Versus Cevical Facet Injection for Patients With Chronic Cervical Pain N/A
Recruiting NCT06154993 - Comparison of Static and Dynamic Opening With Neural Sliding in Cervical Radiculopathy N/A